Energenesis and Taiwan Tanabe Seiyaku Forge Partnership on ENERGI-F703DFU Drug Development

Energenesis Biomedical and Taiwan Tanabe Seiyaku Partnership

On August 6, 2026, Energenesis Biomedical Co., Ltd. announced a significant joint development agreement with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Tanabe Pharma Corporation. This collaboration aims to advance the development of ENERGI-F703DFU, an investigational topical treatment for diabetic foot ulcers (DFU). The agreement marks a pivotal step as both companies prepare for a potential new drug application (NDA) in Taiwan, which could pave the way for later commercialization in key ASEAN markets.

Key Features of the Collaboration

Under this agreement, the two companies will work closely on process technology transfer and chemistry, manufacturing, and controls (CMC) necessary for the NDA submission. Additionally, they plan to explore licensing arrangements for manufacturing and commercialization specifically within Taiwan and select ASEAN markets. This partnership is designed to leverage Energenesis' groundbreaking drug development platform along with Taiwan Tanabe's mature pharmaceutical capabilities.

Dr. Han-Min Chen, Chairman and CEO of Energenesis Biomedical, expressed optimism, stating, "This agreement is an important milestone as ENERGI-F703DFU progresses from late-stage clinical development toward registration and commercial readiness." By uniting Energenesis' expertise in drug development with Taiwan Tanabe's pharmaceutical proficiencies, the companies aim to streamline the NDA preparation process and enhance their commercial prospects across Asia.

Regional Development and Broader Impacts

Taiwan Tanabe, rooted in pharmaceutical excellence, brings vital resources to this partnership. By aligning with Energenesis, they plan to boost efficiency in regulatory navigation and market access. Successful registration in Taiwan is expected to aid in regional expansion efforts throughout ASEAN while supporting the broader out-licensing strategies of Energenesis. This partnership is anticipated to establish a strong foundational framework that could benefit both companies in terms of growth and market presence.

Current Status of ENERGI-F703DFU

The investigational drug, ENERGI-F703DFU, is currently undergoing a Phase III clinical trial across Taiwan and the United States (NCT05930210). Energenesis aims to complete patient recruitment by 2027, followed by data analysis that could lead to an NDA submission, contingent upon successful trial outcomes. The potential efficacy of this topical gel lies in its unique mechanism designed to enhance cellular energy pathways to facilitate wound healing in diabetic foot ulcer patients.

In previously conducted studies, particularly a post-hoc analysis from a Phase II trial, patients responded favorably to ENERGI-F703DFU, showcasing significantly higher complete wound closure rates compared to control groups (36.7% vs. 9.1%, P<0.05). If the ongoing trials yield similar promising results, it is expected that this will substantially elevate access to new treatment options for individuals suffering from diabetic foot ulcers.

About the Companies

Energenesis Biomedical Co., Ltd. is a pioneering clinical-stage biopharmaceutical entity emphasizing the development of therapies focused on cellular energy restoration and repair mechanisms. Their diverse portfolio also includes other candidates targeting various chronic medical conditions, demonstrating a firm commitment to addressing critical unmet medical needs.

Taiwan Tanabe Seiyaku Co., Ltd., established in 1962, is known for its robust approach in the pharmaceutical landscape within Taiwan, enabling powerful synergies through its affiliation with Tanabe Pharma Corporation based in Osaka. This partnership stands to further enrich their development capabilities, contributing invaluable insight to the healthcare environment in the region.

As both companies aim to advance their objectives, the partnership on ENERGI-F703DFU shines a spotlight on the importance of collaborative efforts in drug development, ultimately striving to bring innovative solutions to patients in desperate need.